.
"Commoditization of Specialty Chemicals
Specialty chemicals companies, such as DSM, Evonik, and Altana, enjoyed a period of prosperity until the early 2000s; they were able to realize higher margins than basic chemicals and had the opportunity to differentiate themselves from traditional suppliers in low-cost countries. Recently, however, the financial performance of specialty companies has stagnated as many chemicals have become commodities and opportunities to realize premium prices have evaporated. Western companies with broad specialty portfolios are in the unenviable position of having to change their business models to reflect this sharp drop in pricing power for their products, and the situation is exacerbated by the overall margin squeeze.
Specialty chemicals companies, such as DSM, Evonik, and Altana, enjoyed a period of prosperity until the early 2000s; they were able to realize higher margins than basic chemicals and had the opportunity to differentiate themselves from traditional suppliers in low-cost countries. Recently, however, the financial performance of specialty companies has stagnated as many chemicals have become commodities and opportunities to realize premium prices have evaporated. Western companies with broad specialty portfolios are in the unenviable position of having to change their business models to reflect this sharp drop in pricing power for their products, and the situation is exacerbated by the overall margin squeeze.
...
Pharmaceutical and agrochemical companies must still focus on inventing new entities, but elsewhere in the chemical industry the focus has moved to optimizing processes (especially for basic chemicals), creating new formulations and blends for polymers and other specialty products, and developing new business models (such as pay-for-performance contracts or adding service elements to the initial product offering). This trend is especially strong in Europe, where it has been fostered by the introduction of REACH (registration, evaluation, authorization, and restriction of chemicals) legislation, which limits companies’ ability to register new chemical entities. Thus, active product life cycle management has become a challenge in several chemical segments; consequently, investment in product innovations is under more and more pressure.
Pharmaceutical and agrochemical companies must still focus on inventing new entities, but elsewhere in the chemical industry the focus has moved to optimizing processes (especially for basic chemicals), creating new formulations and blends for polymers and other specialty products, and developing new business models (such as pay-for-performance contracts or adding service elements to the initial product offering). This trend is especially strong in Europe, where it has been fostered by the introduction of REACH (registration, evaluation, authorization, and restriction of chemicals) legislation, which limits companies’ ability to register new chemical entities. Thus, active product life cycle management has become a challenge in several chemical segments; consequently, investment in product innovations is under more and more pressure.
...
In specialty chemicals, three types of players are likely to emerge from the current fragmented landscape. First is the portfolio manager, which follows an M&A strategy that combines “seeking size” and “pick and choose.” These companies will actively buy and sell businesses and consolidate chemical segments within a holding structure that manages businesses with minimal overlaps.
The second type is the integrator, which acquires companies that enhance its horizontal position along the value chain. These companies will be driven especially by the downstream integration of basic chemical companies, which will lead to integrated specialty majors. The third type is the technology boutique, (Moi ici: IMHO a mais interessante para um mundo quase plano e para maiores produtividades) which will primarily focus on organic growth in its niche and only selectively integrate value-adding technology positions.
In specialty chemicals, three types of players are likely to emerge from the current fragmented landscape. First is the portfolio manager, which follows an M&A strategy that combines “seeking size” and “pick and choose.” These companies will actively buy and sell businesses and consolidate chemical segments within a holding structure that manages businesses with minimal overlaps.
The second type is the integrator, which acquires companies that enhance its horizontal position along the value chain. These companies will be driven especially by the downstream integration of basic chemical companies, which will lead to integrated specialty majors. The third type is the technology boutique, (Moi ici: IMHO a mais interessante para um mundo quase plano e para maiores produtividades) which will primarily focus on organic growth in its niche and only selectively integrate value-adding technology positions.
...
New business models are required to ensure outstanding performance as chemical companies grapple with accelerated commoditization. Building a culture that inspires the development of new offerings to generate additional value is mandatory. At the same time, in the few remaining real specialty segments, customer intimacy remains a key success criterion for sustaining the high margins and specialty character of the product."
.
Continua.
